Study guide
1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions
Certified Specialist in Poison Information CSPI
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pharmacology & Toxicology Principles
1.1 Toxicokinetics: Absorption, Distribution, Metabolism, and Elimination Alterations in Overdose 1.2 Toxicodynamics, Receptor Pharmacology, and Dose-Response Relationships 1.3 Cellular and Biochemical Mechanisms of Toxicity 1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions
2 Chapter 2: Poison Center Case Assessment Fundamentals
2.1 Exposure History: The Questions That Change Management 2.2 Toxicologic Calculations: Doses, Concentrations, and Conversions
3 Chapter 3: Analgesics, Opioids & Over-the-Counter Medications
3.1 Acetaminophen Overdose: Pathophysiology, Rumack-Matthew Nomogram, and NAC Protocols 3.2 Salicylates: Pathophysiology, Acid-Base Derangements, and Urinary Alkalinization 3.3 Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Miscellaneous OTC Analgesics 3.4 Opioids, Opioid Toxidrome, and Naloxone Titration 3.5 Cough and Cold Products, Antihistamines, Muscle Relaxants, and Local Anesthetics
4 Chapter 4: Psychotropic & Neurologic Medications
4.1 Tricyclic and Cyclic Antidepressants: Cardiotoxicity, ECG Findings, and Bicarbonate Therapy 4.2 SSRIs, SNRIs, Novel Antidepressants, and Serotonin Syndrome 4.3 Antipsychotics, Neuroleptic Malignant Syndrome, and Lithium Neurotoxicity 4.4 Benzodiazepines, Z-drugs, Barbiturates, and Major Anticonvulsants
5 Chapter 5: Cardiovascular Drugs & Substances of Abuse
5.1 Beta-Blockers, Calcium Channel Blockers, and High-Dose Insulin Euglycemia Therapy 5.2 Digoxin and Cardiac Glycosides: Mechanism, Arrhythmias, and Digoxin Immune Fab 5.3 Sympathomimetics, Cocaine, Amphetamines, Synthetic Cannabinoids, and Hallucinogens 5.4 Caffeine, Theophylline, and Over-the-Counter Stimulants 5.5 Cannabis, GHB, Nitrites, and Nicotine Products
6 Chapter 6: Endocrine, Antimicrobial & Miscellaneous Medications
6.1 Antidiabetic Agents, Metformin Lactic Acidosis, and Thyroid Hormone 6.2 Antimicrobials, Vitamins and Minerals, and Veterinary Products
7 Chapter 7: Household, Chemical & Inhalational Toxins
7.1 Caustic and Corrosive Ingestions: Acids vs. Alkalis, Tissue Necrosis, and Endoscopic Grading 7.2 Cleaning Products, Personal Care Products, and Household Chemicals 7.3 Hydrocarbons and Halogenated Solvents: Aspiration Risks and Myocardial Sensitization 7.4 Carbon Monoxide, Cyanide, Hydrogen Sulfide, and Inhalational Irritants
8 Chapter 8: Pesticides, Heavy Metals & Toxic Alcohols
8.1 Organophosphates, Carbamates, Pyrethroids, and Cholinesterase Antidotes 8.2 Rodenticides, Herbicides, Repellents, and Other Pesticides 8.3 Ethylene Glycol, Methanol, and Isopropanol: Metabolism, Osmolal Gaps, and Fomepizole 8.4 Lead, Mercury, Arsenic, Iron Toxicity, and Chelation Protocols
9 Chapter 9: Toxic Plants, Mushrooms & Foodborne Toxins
9.1 Toxic Plants: Cardiac Glycosides, Anticholinergics, Nicotinics, and Sodium Channel Activators 9.2 Oxalate, Irritant, Hallucinogenic, and Stimulant Plants 9.3 Mushroom Poisoning: Amatoxins, Monomethylhydrazine, Muscarine, and Coprine 9.4 Scombroid, Ciguatera, Tetrodotoxin, Paralytic Shellfish, and Botulism 9.5 Bacterial Foodborne Illness and Food Poisoning Triage
10 Chapter 10: Envenomations & Bites
10.1 North American Pit Vipers (Crotalinae): Envenomation Assessment and Antivenom Management 10.2 Elapid Snakebites (Coral Snakes): Neurotoxicity, Clinical Course, and Antivenin 10.3 Black Widow, Brown Recluse Spiders, and Bark Scorpion Stings 10.4 Hymenoptera Stings, Ticks, and Other Arthropods 10.5 Marine Envenomations: Jellyfish, Stingrays, Catfish, and Lionfish
11 Chapter 11: Clinical Assessment, Toxidromes & Triage
11.1 Recognition of Classic Toxidromes and Vital Sign Pattern Analysis 11.2 Severity Assessment, Exposure Urgency, and Poison Center Telephone Triage Flow 11.3 Home Observation vs. Emergency Department Referral Decision-Making 11.4 Diagnostic Toxicology: Acid-Base Analysis, Gaps, ECG Intervals, and Drug Testing
12 Chapter 12: Decontamination, Antidotes & Elimination
12.1 Gastrointestinal Decontamination: Activated Charcoal, Whole Bowel Irrigation, and Contraindications 12.2 Essential Poison Center Antidotes: Indications, Mechanisms, and Titration Pearls 12.3 Enhanced Elimination: Urinary Alkalinization, MDAC, Hemodialysis, and Hemoperfusion 12.4 Resuscitation and Supportive Care: Seizures, Hyperthermia, and Hemodynamic Shock
13 Chapter 13: Pediatric Poisoning & High-Risk Hazards
13.1 Pediatric "One-Pill-Can-Kill" Agents and Pediatric Toxic Dose Thresholds 13.2 Button Batteries, Rare-Earth Magnets, and Expandable Foreign Bodies 13.3 Developmental Ingestion Patterns, Liquid Detergent Pods, and Essential Oils
14 Chapter 14: Communication, NPDS Documentation & Prevention
14.1 Emergency Call Communication, Panicked Callers, and Healthcare Provider Consultations 14.2 National Poison Data System (NPDS) Coding Standards and Medical Outcome Categorization 14.3 Scheduled Follow-up Protocols, Medical Toxicologist Consultation Triggers, and Public Health Surveillance 14.4 Evidence-Based Poison Prevention, PPPA Regulations, and Community Outreach
1.4 Hepatic Biotransformation, Phase I/II Reactions, and CYP450 Interactions
Key Takeaways Explain This Topic AI
Hepatic biotransformation converts lipophilic xenobiotics into excretable hydrophilic metabolites through Phase I functionalization (CYP450 oxidation, reduction, hydrolysis) and Phase II synthetic conjugation (glucuronidation, sulfation, glutathione binding).
Major CYP isoenzymes (CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2, CYP2E1) display distinct substrate profiles, environmental induction, and pharmacological inhibition, governing critical drug-drug interactions.
Metabolic bioactivation converts relatively inert parent xenobiotics into lethal poisons, as demonstrated by the conversion of methanol to formic acid, ethylene glycol to glycolic and oxalic acids, and acetaminophen to NAPQI.
Pharmacogenomic polymorphisms (e.g., NAT2 acetylator status and CYP2D6 metabolizer phenotypes) cause dramatic inter-individual variability in toxicity, therapeutic failure, or fatal opioid toxicity from prodrugs.
Last updated: September 2026
Lipophilic xenobiotics readily cross biological membranes and would undergo near-complete passive reabsorption across renal tubular epithelium, persisting indefinitely in the body without enzymatic biotransformation. Hepatic biotransformation converts lipophilic chemicals into polar, water-soluble, ionized metabolites that can be excreted in bile and urine.
Biotransformation proceeds through two sequential enzyme phases:
Phase I Reactions (Functionalization) : Introduces or unmasks a polar functional group (-OH, -NH₂, -SH, or -COOH) via oxidation, reduction, or hydrolysis.
Phase II Reactions (Conjugation) : Covalently couples an endogenous, highly water-soluble polar moiety (glucuronic acid, sulfate, glutathione, acetate, or amino acids) to the functional group. Lipophilic Xenobiotic → [Phase I: CYP450] → Functionalized Intermediate → [Phase II: Transferase] → Hydrophilic Conjugate → Excretion
- ↓ (Overdose / Saturation)
- Reactive Toxic Metabolite (NAPQI, Epoxides)
- Phase I Biotransformation: The Cytochrome P450 Superfamily
The Cytochrome P450 (CYP) superfamily consists of membrane-bound, heme-thiolate monooxygenases localized predominantly within the smooth endoplasmic reticulum of hepatocytes and enterocytes. The canonical monooxygenase reaction requires molecular oxygen, NADPH, and the electron-transfer protein NADPH-cytochrome P450 reductase : RH + O 2 + NADPH + H + → CYP ROH + H 2 O + NADP + \text{RH} + \text{O}_2 + \text{NADPH} + \text{H}^+ \xrightarrow{\text{CYP}} \text{ROH} + \text{H}_2\text{O} + \text{NADP}^+ RH + O 2 + NADPH + H + CYP ROH + H 2 O + NADP +
Six specific CYP isoenzymes account for more than 90% of all clinically significant drug biotransformation:
1. CYP3A4/5
Significance : The most abundant CYP enzyme in humans, comprising ~30% of hepatic CYP content and ~70% of intestinal mucosal CYP. Metabolizes over 50% of prescription pharmaceuticals.
Key Substrates : Calcium channel blockers (amlodipine, diltiazem, verapamil), statins (simvastatin, atorvastatin), fentanyl, methadone, midazolam, carbamazepine, quetiapine, cyclosporine, colchicine.
Potent Inducers : Rifampin, carbamazepine, phenytoin, phenobarbital, and St. John's wort (via pregnane X receptor [PXR] activation).
Potent Inhibitors : Ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, cobicistat, diltiazem, and grapefruit juice (furanocoumarins like bergamottin, which selectively and irreversibly destroy intestinal mucosal CYP3A4).
Toxicological High-Yield Risk : Co-administration of a potent CYP3A4 inhibitor with colchicine blocks colchicine elimination, triggering multi-organ failure, bone marrow aplasia, and death. Co-ingestion with simvastatin causes massive rhabdomyolysis.
2. CYP2D6
Significance : Accounts for only ~2% of total hepatic CYP content, yet metabolizes 20–25% of therapeutic drugs. Highly polymorphic; cannot be clinically induced by environmental xenobiotics.
Key Substrates : Tricyclic antidepressants (amitriptyline, nortriptyline), beta-blockers (metoprolol, carvedilol), venlafaxine, haloperidol, dextromethorphan, and opioids ( codeine and tramadol , which are prodrugs, plus hydrocodone and oxycodone , which form more potent metabolites).
Potent Inhibitors : Fluoxetine, paroxetine, bupropion, quinidine.
Toxicological High-Yield Risk : Fluoxetine or bupropion added to a stable regimen of codeine blocks conversion to morphine, eliminating analgesia. Conversely, inhibition of TCA metabolism produces lethal cardiotoxicity.
3. CYP2C9
Significance : Primary clearance pathway for narrow-therapeutic-index acidic drugs.
Key Substrates : S-warfarin (the clinically potent enantiomer), phenytoin, sulfonylureas (glipizide, glyburide).
Potent Inhibitors : Fluconazole, amiodarone, sulfamethoxazole-trimethoprim (Bactrim), metronidazole.
Toxicological High-Yield Risk : Initiating a course of fluconazole or Bactrim in a patient on stable warfarin arrests S-warfarin clearance, producing severe coagulopathy (INR >10) and life-threatening hemorrhage within 3 to 5 days. Added to glipizide, it triggers refractory hypoglycemia.
4. CYP2C19
Significance : Critical for the bioactivation of thienopyridine antiplatelet prodrugs.
Key Substrates : Clopidogrel, diazepam, omeprazole, citalopram, voriconazole.
Potent Inhibitors : Omeprazole, fluvoxamine, ticlopidine.
Toxicological High-Yield Risk : Clopidogrel requires two-step hepatic CYP activation; poor metabolizers or patients taking strong inhibitors fail to form the active platelet-inhibiting thiol metabolite, risking acute stent thrombosis.
5. CYP1A2
Significance : Constitutively expressed in liver; uniquely induced by polycyclic aromatic hydrocarbons.
Key Substrates : Theophylline, caffeine, clozapine, olanzapine, tizanidine, acetaminophen (minor pathway).
Potent Inducers : Tobacco smoke and cannabis smoke (polycyclic aromatic hydrocarbons activating the aryl hydrocarbon receptor [AhR]), chargrilled meats, carbamazepine, omeprazole.
Potent Inhibitors : Ciprofloxacin, fluvoxamine.
Toxicological High-Yield Risk : A patient stabilized on clozapine or theophylline who is prescribed ciprofloxacin experiences immediate enzyme inhibition, precipitating acute clozapine toxicity (seizures, sedation, hypotension) or theophylline toxicity (seizures, refractory tachyarrhythmias).
6. CYP2E1
Significance : Primary catalyst for ethanol, acetone, and volatile halogenated hydrocarbons; major toxifying enzyme in acetaminophen poisoning.
Key Substrates : Ethanol, acetaminophen, carbon tetrachloride, halothane, isoniazid.
Inducers : Chronic ethanol consumption, isoniazid, fasting/starvation, diabetic ketosis.
Toxicological High-Yield Risk : Chronic alcoholics have elevated hepatic CYP2E1 levels. Following acute APAP ingestion, a markedly higher proportion of acetaminophen is bioactivated into toxic NAPQI, substantially lowering the hepatotoxic threshold dose.
Non-CYP Phase I Enzymes
Alcohol Dehydrogenase (ADH) : Cytosolic zinc metalloenzyme that oxidizes primary alcohols to aldehydes (ethanol to acetaldehyde; methanol to formaldehyde; ethylene glycol to glycolaldehyde).
Aldehyde Dehydrogenase (ALDH) : Mitochondrial enzyme converting aldehydes to carboxylic acids (acetaldehyde to acetate; formaldehyde to formic acid; glycolaldehyde to glycolic acid). Blocked by disulfiram and coprine (found in Coprinopsis atramentaria mushrooms).
Carboxylesterases & Butyrylcholinesterase (Pseudocholinesterase) : Plasma and tissue esterases that rapidly hydrolyze ester-containing xenobiotics, including cocaine, heroin, succinylcholine, and local anesthetics.
Phase II Conjugation Pathways
Phase II enzymes attach hydrophilic endogenous co-substrates to polar chemical handles, almost always terminating biological activity and facilitating rapid biliary or urinary excretion.
Phase II Pathway Enzyme Class Endogenous Co-Substrate Capacity / Characteristics High-Yield Xenobiotic Substrates
Glucuronidation UDP-glucuronosyltransferases (UGTs) UDP-glucuronic acid (UDPGA) High capacity ; most common Phase II reaction. Saturated only in massive overdose. Acetaminophen, Morphine, Lorazepam, Bilirubin, NSAIDs
Sulfation Sulfotransferases (SULTs) 3'-phosphoadenosine-5'-phosphosulfate (PAPS) High affinity, low capacity ; saturated early at low concentrations due to PAPS depletion. Acetaminophen, Steroids, Methyldopa, Phenols
Glutathione Conjugation Glutathione S-transferases (GSTs) Glutathione (tripeptide: Glu-Cys-Gly) Critical defense against electrophiles. Intracellular depletion (<20–30%) permits cell death. NAPQI (APAP), Ethacrynic acid, Halogenated solvents
Acetylation N-acetyltransferases (NAT1, NAT2) Acetyl-CoA Genetically bimodal (slow vs. rapid acetylators). Isoniazid, Hydralazine, Procainamide, Dapsone, Sulfonamides
Amino Acid Conjugation Glycine N-acyltransferase Glycine Converts carboxylic acids into excretable hippurates; saturates in overdose. Salicylic acid (forming salicyluric acid), Benzoic acid
Enzyme Induction vs. Inhibition Dynamics Enzyme Induction: Nuclear Receptors (PXR/CAR/AhR) → Gene Transcription → New Protein Synthesis (Days to Weeks)
- Enzyme Inhibition: Direct Competitive / Mechanism-Based Binding to Active Site → Immediate Arrest (Hours)
- Pharmacokinetics of Induction
Induction is not an acute, instantaneous event. Xenobiotics bind to cytoplasmic/nuclear receptors—such as the Pregnane X Receptor (PXR) , Constitutive Androstane Receptor (CAR) , or Aryl Hydrocarbon Receptor (AhR) . The ligand-receptor complex translocates to the nucleus, heterodimerizes with the Retinoid X Receptor (RXR), and binds response elements in the promoter region of CYP genes, up-regulating mRNA transcription and de novo enzyme synthesis.
Time Course : Requires 7 to 14 days of continuous exposure to reach maximal enzyme capacity.
Offset : Persists for 1 to 3 weeks after the inducing agent is discontinued, while the excess enzyme pool degrades.
Pharmacokinetics of Inhibition
Inhibition occurs immediately upon the inhibitor reaching the enzyme site:
Competitive Inhibition : Reversible; the inhibitor competes directly with substrate for the catalytic binding pocket. Onset is immediate, resolving as the inhibitor is cleared.
Mechanism-Based ("Suicide") Inactivation : The enzyme bioactivates the inhibitor into a reactive intermediate that covalently bonds to the heme or apoprotein moiety of the enzyme, permanently destroying catalytic activity (e.g., grapefruit juice furanocoumarins inactivating intestinal CYP3A4). Restoration requires de novo enzyme synthesis.
Bioactivation: Generation of Toxic Metabolites
Many parent xenobiotics possess low intrinsic toxicity but are transformed by endogenous enzymes into lethal cytotoxins ( bioactivation ): Methanol ──(ADH)──> Formaldehyde ──(ALDH)──> Formic Acid (Complex IV Toxin, Retinal Necrosis)
Ethylene Glycol ──(ADH)──> Glycolaldehyde ──(ALDH)──> Glycolic Acid (Severe Acidosis) ──> Oxalic Acid (Renal AKI)
- Acetaminophen ──(CYP)──> NAPQI (Glutathione Depletion → Hepatocellular Centrilobular Necrosis)
- Codeine ──(2D6)──> Morphine (Respiratory Depression; Fatal in Ultra-Rapid Metabolizers)
- Toxic Alcohols and ADH Inhibition
Methanol : Metabolized by ADH to formaldehyde, then rapidly by ALDH to formic acid . Formic acid inhibits cytochrome oxidase, causing profound anion gap metabolic acidosis, optic disc hyperemia, retinal edema, and blindness.
Ethylene Glycol : Metabolized by ADH to glycolaldehyde, then to glycolic acid , which causes life-threatening metabolic acidosis. Glycolic acid is further converted to glyoxylic acid and oxalic acid . Oxalic acid precipitates with ionized calcium, forming insoluble calcium oxalate monohydrate crystals in renal tubules, leading to acute kidney injury, flank pain, and systemic hypocalcemia.
Antidotal Strategy : Fomepizole (4-methylpyrazole) is a competitive inhibitor of ADH with an affinity approximately 8,000 times greater than ethanol (Ki ≈ 0.1 μM). Administering fomepizole halts toxic alcohol bioactivation immediately, allowing un-metabolized parent alcohols to be cleared safely via hemodialysis or excreted in urine.
Pharmacogenomics in Clinical Toxicology
Genetic polymorphisms in drug-metabolizing enzymes create dramatic disparities in patient susceptibility to toxicity:
1. N-Acetyltransferase-2 (NAT2) Polymorphism
Human populations exhibit a genetically determined bimodal distribution of NAT2 activity:
Slow Acetylators (Homozygous Recessive) : Possess reduced NAT2 activity (~50% of the Caucasian and African-American populations).
Isoniazid (INH) Neurotoxicity : Slow acetylators eliminate parent INH poorly. Elevated parent INH reacts with pyridoxal-5'-phosphate and inhibits pyridoxine phosphokinase, causing functional pyridoxine (vitamin B6) deficiency . Because pyridoxine is the obligate co-factor for glutamic acid decarboxylase (GAD), central synthesis of the inhibitory neurotransmitter GABA ceases, precipitating intractable status epilepticus that responds only to IV pyridoxine replacement.
Drug-Induced Lupus Erythematosus (DILE) : Slow acetylators have a dramatically higher risk of developing DILE when treated with hydralazine or procainamide .
Dapsone : Slower acetylation shunts dapsone into CYP-mediated N-hydroxylation, generating toxic dapsone hydroxylamine, which causes severe methemoglobinemia and hemolysis.
Rapid Acetylators : Clear parent INH rapidly, but generate larger quantities of monoacetylhydrazine, which can be bioactivated into hepatotoxic intermediates.
2. CYP2D6 Genetic Polymorphisms
The CYP2D6 gene is highly polymorphic, with over 100 allelic variants categorizing patients into four distinct phenotypes:
Poor Metabolizers (PM) : Carry two non-functional alleles (~7–10% of Caucasians). Cannot bioactivate prodrugs (codeine, tramadol) into active analgesics (morphine, M1); experience complete therapeutic failure.
Intermediate Metabolizers (IM) : Reduced metabolic activity.
Normal / Extensive Metabolizers (NM/EM) : Normal metabolic function.
Ultra-Rapid Metabolizers (UM) : Carry gene duplications or amplifications (up to 13 copies of the functional CYP2D6 gene), seen in up to 10–29% of North African, Ethiopian, and Arab populations.
Tragic Clinical Scenario: A nursing mother who is a CYP2D6 Ultra-Rapid Metabolizer takes standard therapeutic doses of codeine for post-partum pain. Her liver rapidly bioactivates codeine into massive concentrations of morphine, which pass into breast milk. Her breastfed infant develops severe lethargy, pinpoint pupils, apnea, and fatal morphine toxicity. Similar post-tonsillectomy pediatric deaths led to FDA contraindications for codeine and tramadol in children under 12 years of age.
3. Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency
G6PD is the rate-limiting enzyme of the hexose monophosphate shunt, the sole cellular pathway generating NADPH in mature erythrocytes. Red blood cells require NADPH to regenerate reduced glutathione (GSH), which neutralizes ambient oxidative stress.
When patients with X-linked G6PD deficiency are exposed to oxidant xenobiotics ( dapsone, rasburicase, primaquine, methylene blue ), erythrocytes cannot regenerate GSH. Unchecked oxidative stress oxidizes hemoglobin sulfhydryl groups and peroxidizes membranes, precipitating Heinz body formation, acute intravascular hemolysis, and hemoglobinuric renal failure .